ENG and neoplasm: Herein, we showed that the bispecific hEND-CD3/BiTE antibody we developed specifically targeted endoglin+ cells, including those ectopically expressing endoglin (293T-hE) and normal, as well as tumor endothelial cells expressing endogenous endoglin (HUVEC and Td-EC).